Related Experiment Video
Updated: Jun 27, 2026
A Flow Cytometry-Based Cytotoxicity Assay for the Assessment of Human NK Cell Activity
Published on: August 9, 2017
Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs
A Pessina1, D Parent-Massin, B Albella
1Department of Public Health-Microbiology-Virology, Faculty of Medicine, University of Milan, Via Pascal 36, 20133 Milan, Italy. augusto.pessina@unimi.it
Abstract:
Megakaryocytopoiesis gives rise to platelets by proliferation and differentiation of lineage-specific progenitors, identified in vitro as Colony Forming Unit-Megakaryocytes (CFU-Mk). The aim of this study was to refine and optimize the in vitro Standard Operating Procedure (SOP) of the CFU-Mk assay for detecting drug-induced thrombocytopenia and to prevalidate a model for predicting the acute exposure levels that cause maximum tolerated decreases in the platelets count, based on the correlation with the maximal plasma concentrations (C max) in vivo. The assay was linear under the SOP conditions, and the in vitro endpoints (percentage of colonies growing) were reproducible within and across laboratories. The protocol performance phase was carried out testing 10 drugs (selected on the base of their recognised or potential in vivo haematotoxicity, according to the literature). Results showed that a relationship can be established between the maximal concentration in plasma (C max) and the in vitro concentrations that inhibited the 10-50-90 percent of colonies growth (ICs). When C max is lower than IC10, it is possible to predict that the chemicals have no direct toxicity effect on CFU-Mk and could not induce thrombocytopenia due to bone marrow damage. When the C max is higher than IC90 and/or IC50, thrombocytopenia can occur due to direct toxicity of chemicals on CFU-Mk progenitors.
Insights
This study optimized the Colony Forming Unit-Megakaryocytes (CFU-Mk) assay to predict drug-induced thrombocytopenia. The assay correlates in vivo drug exposure (C max) with in vitro effects on megakaryocyte progenitors, aiding toxicity assessment.
Area of Science:
- Hematology
- Toxicology
- Drug Development
Background:
- Megakaryocytopoiesis, the process of platelet formation, involves progenitor cells identified as Colony Forming Unit-Megakaryocytes (CFU-Mk).
- Drug-induced thrombocytopenia is a significant clinical concern requiring reliable predictive assays.
- Existing methods for assessing drug toxicity on megakaryopoiesis can be refined for greater accuracy and efficiency.
Purpose of the Study:
- To optimize and validate the in vitro Colony Forming Unit-Megakaryocyte (CFU-Mk) assay for detecting drug-induced thrombocytopenia.
- To prevalidate a predictive model correlating in vivo drug exposure (C max) with in vitro effects on CFU-Mk.
- To establish a reliable method for assessing the potential of drugs to cause decreased platelet counts.
Main Methods:
- Refinement and optimization of the standard operating procedure (SOP) for the in vitro CFU-Mk assay.
- Testing the assay's linearity, reproducibility, and performance using 10 selected drugs with known or potential hematotoxicity.
- Correlating maximal plasma concentrations (C max) in vivo with in vitro concentrations inhibiting 10-90% of CFU-Mk colony growth (IC10-IC90).
Main Results:
- The optimized CFU-Mk assay demonstrated linearity and reproducibility across laboratories.
- A significant correlation was established between in vivo C max and in vitro inhibitory concentrations (IC10-IC90).
- The assay successfully predicted whether drugs would cause thrombocytopenia based on their C max relative to IC values.
Conclusions:
- The optimized in vitro CFU-Mk assay is a reliable tool for predicting drug-induced thrombocytopenia.
- The assay allows for the prediction of direct toxicity on megakaryocyte progenitors based on drug plasma concentrations.
- This validated model can aid in early drug development by identifying potential hematotoxic agents.
